In October 2007, the FDA announced that the labeling for all PDE5 inhibitors, which include tadalafil, needs a additional prominent warning in the probable hazard of unexpected Listening to loss as the results of put up-marketing and advertising experiences of short term deafness connected with usage of PDE5 inhibitors.[19]Any health-related inform